Loading...
XJPX
4577
Market cap238mUSD
Oct 09, Last price  
1,318.00JPY
1D
0.69%
1Q
5.44%
Jan 2017
-35.68%
IPO
2.16%
Name

Daito Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XJPX:4577 chart
P/E
11.98
P/S
0.75
EPS
109.97
Div yield, %
2.86%
Shrs. gr., 5y
-0.42%
Rev. gr., 5y
0.78%
Revenues
50.65b
+0.01%
20,756,173,00021,522,614,00022,678,058,00025,225,033,00027,151,470,00028,956,292,00031,196,388,00034,062,366,00036,331,198,00037,973,361,00039,883,625,00041,135,053,00044,997,108,00048,709,171,00043,464,000,00045,101,000,00046,895,000,00050,643,000,00050,650,000,000
Net income
3.16b
+65.67%
751,930,000692,964,000752,385,000990,619,0001,389,140,0001,786,636,0001,811,396,0002,246,122,0002,566,419,0002,656,281,0003,041,941,0003,513,028,0003,944,713,0004,246,457,9994,667,000,0003,599,000,0003,294,000,0001,908,000,0003,161,000,000
CFO
9.38b
+59.01%
1,468,296,0001,020,926,0002,167,203,0002,829,083,0003,342,888,0002,541,424,0002,744,650,0003,739,312,0002,948,858,0005,069,743,0005,465,342,0006,888,157,0004,306,265,0005,182,527,0004,370,000,0004,155,000,0005,182,000,0005,897,000,0009,377,000,000
Dividend
Nov 30, 202622.5 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Daito Pharmaceutical Co.,Ltd. is a global entity primarily involved in the creation and sale of a diverse range of pharmaceutical products. Their offerings span active pharmaceutical ingredients (APIs) and chemical intermediates, alongside both prescription and over-the-counter (OTC) medications, and home-delivered medicines. These products are available in various formats, including tablets, capsules, lozenges, granules, and powdered forms. Beyond its own brand, the company also provides contract manufacturing services, developing medicinal formulations for other pharmaceutical firms. Additionally, Daito Pharmaceutical markets health food products. Established in 1942, it was initially known as Daito Corporation, changing to its current name in 1992, and maintains its headquarters in Toyama, Japan.

Key people

Yasunobu Ohtsuga
Chairman of the Board, Chief Executive Officer, Representative Director · since 2024
Kenji Otsuga
Executive Officer, Chief Financial Officer · since 2025
Kazushige Hizume
Managing Executive Officer, Chief Director of Pharmaceuticals, Director · since 2021
Hiroshi Kubota
Managing Executive Officer, Chief Director of Reliability Assurance, Manager of Pharmaceutical Affairs Office · since 2023
Yutaka Kuwashima
Managing Executive Officer, Chief Director of Drug Substance, Manager of Tokyo Office · since 2022
Kiyoshi Takami
Managing Executive Officer, Manager of Shimookui Office · since 2025
Norio Kishi
Executive Officer, Chief Director of Purchasing & Logistics, Director of International Business, Manager of Osaka Office, President and CEO of Subsidiary · since 2022
Atsushi Kosugi
Executive Officer, Chief Director of Research and Development, Manager of Formulation Research Office · since 2025
Masahiko Mouri
Executive Officer, Deputy Chief Director of Production, Director of API Production, Manager of API Technical Office · since 2024
Yoshinori Nakajima
Executive, Deputy Chief Director of Main Production Unit, Director of Production Management · since 2024
Ryosuke Sato
Executive Officer, Chief Director of Active Pharmaceutical Ingredients, Director of Raw Materials · since 2025
Eiichi Takata
Executive Officer, Chief Director of Purchasing and Logistics · since 2025
Toru Ishida
Managing Executive Officer, Chief Director of Production, Director of Formulation Manufacturing, Manager of Environment and Safety Office, Director · since 2025
Hiroshi Matsumori
President, Chief Executive Officer, Representative Director · since 2025
Hitoshi Hori
Independent Director · since 2015
Kimiko Komatsu
Independent Director · since 2022
Atsushi Saino
Independent Director · since 2017
Minori Uchida
Independent Director · since 2025
Ichizo Yamamoto
Independent Director · since 2015
URL
https://www.daitonet.co.jp/
IPO date
Mar 24, 2010
Employees
1,011
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑052025‑052024‑052023‑052022‑052021‑052020‑052019‑052018‑052017‑05
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT